Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Arteaga

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|May 25, 2023
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responsesAmrendra Kumar, Vijay Ramani, Vijaya Bharti, et al.
Clinical Drug Investigation|January 15, 2019
Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast CancerGriet Hoste, Laurence Slembrouck, Lynn Jongen, et al.
Clinical Drug Investigation|September 7, 2018
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast CancerGriet Hoste, Laurence Slembrouck, Lynn Jongen, et al.
Lancet Regional Health. Americas|January 7, 2025
Climate change, migration, and health: perspectives from Latin America and the CaribbeanCarolina Batista, Michael Knipper, Ana Cristina Sedas, et al.
Future Oncology (London, England)|April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancerHope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
Arquivos Brasileiros De Cardiologia|March 22, 2023
Immediate Results after Multiple Arterial Grafts in Coronary Artery Bypass Graft Surgery in the São Paulo State: Cross Cohort StudyRaúl Armando Micalay Paredes, Gabrielle Barbosa Borgomoni, Anny Kátia Puchalski Micalay, et al.
Cell Reports|April 7, 2021
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumorsRoman V Uzhachenko, Vijaya Bharti, Zhufeng Ouyang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersBhuvanesh Dave, Ilenia Migliaccio, M Carolina Gutierrez, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
Breast Cancer Research : BCR|December 28, 2019
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancersSuryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|May 25, 2023
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responsesAmrendra Kumar, Vijay Ramani, Vijaya Bharti, et al.
Clinical Drug Investigation|January 15, 2019
Correction to: Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast CancerGriet Hoste, Laurence Slembrouck, Lynn Jongen, et al.
Clinical Drug Investigation|September 7, 2018
Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast CancerGriet Hoste, Laurence Slembrouck, Lynn Jongen, et al.
Lancet Regional Health. Americas|January 7, 2025
Climate change, migration, and health: perspectives from Latin America and the CaribbeanCarolina Batista, Michael Knipper, Ana Cristina Sedas, et al.
Future Oncology (London, England)|April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancerHope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
Arquivos Brasileiros De Cardiologia|March 22, 2023
Immediate Results after Multiple Arterial Grafts in Coronary Artery Bypass Graft Surgery in the São Paulo State: Cross Cohort StudyRaúl Armando Micalay Paredes, Gabrielle Barbosa Borgomoni, Anny Kátia Puchalski Micalay, et al.
Cell Reports|April 7, 2021
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumorsRoman V Uzhachenko, Vijaya Bharti, Zhufeng Ouyang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersBhuvanesh Dave, Ilenia Migliaccio, M Carolina Gutierrez, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.
Breast Cancer Research : BCR|December 28, 2019
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancersSuryavathi Viswanadhapalli, Shihong Ma, Gangadhara Reddy Sareddy, et al.
Pageof 4